When Solidaris Capital filed suit in Dallas County, the case was quickly framed by some outlets as a familiar cautionary tale: a biotech venture accused of fraud, investors allegedly misled, regulators lurking in the background. Words like “scheme,” “deception,” and even “FDA issues” began appearing in headlines and commentary.
But a closer look at the facts — the contracts, the timing, the money, and the law — tells a very different story.
Despite how it has been described, the Dallas lawsuit is not a fraud case. It does not allege securities fraud. It does not allege FDA misrepresentation. No regulator is a party to the case, and no regulatory violation is pleaded.
Instead, the lawsuit is framed as a trade secret dispute. Solidaris alleges that after a contractual relationship ended, proprietary information was misused.
That framing matters, because trade secret law is narrow, technical, and unforgiving. To qualify as a trade secret, information must be genuinely secret, derive economic value from that secrecy, and be subject to reasonable efforts to keep it confidential.
Here, those requirements are difficult to reconcile with the facts.
The materials Solidaris now claims were proprietary were, throughout 2024, freely accessible via a shared Dropbox. No meaningful access controls were in place. No secrecy protocols were enforced. And no patent application was filed until January 11, 2025 — months after the relationship ended.
More fundamentally, the alleged “trade secrets” are not inventions at all. They are applications of the U.S. tax code. The Internal Revenue Code is public law. Its mechanics, incentives, and limitations are available to anyone willing to read the statute. Under the America Invents Act of 2011, tax strategies and interpretations of public law are not patentable, precisely because they belong to the public domain.
That reality raises an obvious question: if this was truly proprietary intellectual property, why are at least ten other companies operating materially similar programs — and why has Solidaris not sued them?
Part of the confusion stems from the assumption that the programs at issue were the same. They were not.
The program developed by Mark Bianchi and Head Genetics was gift-card-based. It relied on conventional LLC structures and straightforward transactional mechanics. It did not monetize intellectual property, and it did not use the Series LLC architecture that Solidaris employs in its own offerings.
The overlap between the two programs exists only where any tax-advantaged structure must overlap: at the level of public statute. That overlap does not transform a lawful competitor into a trade secret thief.
What changed was not the law, or the structure, but the economics. Clients followed Mark Bianchi. Solidaris lost anticipated revenue. The lawsuit followed.
Another persistent theme in coverage has been the suggestion that the underlying medical technology did not exist, or that it was exaggerated to attract investment. That narrative does not survive basic diligence.
The concussion-related devices exist. Manufacturers have been paid. Clinical studies have been approved. Work is ongoing.
Crucially, Head Genetics did not invent the technology. It licenses the intellectual property from RapidDX, an entity with years of research behind it and a documented history of communications with the FDA. That licensing model — where development and commercialization are separated — is standard in medical diagnostics and biotech.
Portraying the technology as “fake” conflates corporate formation dates with research history and ignores how IP licensing actually works in practice.
Allegations that investor funds were misused have also circulated widely, often without context.
The financial records tell a different story. Funds were deployed in accordance with the private placement memorandum and within SEC-accepted expense thresholds, roughly 25 percent. Those expenses were reported on tax returns. Independent audits were conducted. IOLTA accounts were used. More than half of investor funds remain reserved, earmarked to ensure charitable commitments, manufacturing obligations, and clinical studies are fully funded.
That stands in contrast to Solidaris’ own structures, where expense ratios approach 75 percent and where expenses do not consistently reduce investor basis as required. In some cases, losses do not appear in Box 1 of K-1s at all. Valuation inconsistencies appear across documents, with offering materials suggesting 20x multiples while K-1s reflect 5x and Forms 8283 are signed without stated values.
Against that backdrop, claims of misuse look less like discovery and more like deflection.
Perhaps the most telling part of the story is how it ended.
Mark Bianchi terminated the relationship in October 2024 after reviewing documents that raised serious legal concerns. The separation was documented in writing. It was not hostile. And it came at significant personal cost.
By walking away, Bianchi earned nothing in 2024. Had he stayed, he stood to earn millions. He chose instead to disengage.
That decision does not fit the narrative of opportunism or misconduct. It fits the narrative of someone choosing compliance over compensation.
Finally, the lawsuit cannot be separated from what followed it. Whistleblower reports were filed with multiple federal agencies, including the SEC, the IRS, and the Senate Finance Committee — not by Solidaris or its principal, but against them. The identity of the whistleblower is unknown, but the direction of scrutiny is not.
As larger and more reputable outlets begin to examine the underlying structures, the lawsuit increasingly appears less like a revelation and more like a response.
This is not a story about fake technology, stolen secrets, or regulatory fraud. It is a story about a business relationship that ended, clients who chose a different advisor, and a lawsuit that has been rhetorically expanded far beyond what it actually alleges.
In that sense, the most important correction is also the simplest one: the facts matter, and the pleadings matter. When the two are examined closely, the sensational narrative dissolves.